Search
Now showing items 1-10 of 11
Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy
(2018-01)
It had long been believed that placebo response rates in antidepressant trials have been increasing and that they were responsible for rising numbers of so-called failed antidepressant trials. Two recent systematic reviews ...
How pharmacist prescribers can help meet the mental health consequences of COVID-19
(2020-11)
We suggest that Mental Health Trusts
should urgently develop prescribing roles
for specialist mental health pharmacists,
which are integrated within mental health
teams. In these roles, prescribing pharmacists can ...
A web-based clinical decision tool to support treatment decision-making in psychiatry: a pilot focus group study with clinicians, patients and carers
(2017)
Background
Treatment decision tools have been developed in many fields of medicine, including psychiatry, however benefits for patients have not been sustained once the support is withdrawn. We have developed a web-based ...
Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study
(2019-04-15)
In medicine, algorithms can inform treatment decisions by combining the most up-to-date evidence about side effect profiles of medications, which are comparable in efficacy. Their use provides opportunities for improved ...
Rischio di mortalità con i farmaci antipsicotici nella popolazione psichiatrica anziana? Una revisione sistematica della letteratura
(2016)
Scopo dello studio: In Italia, gli anziani raggiungono quasi un quarto della popolazione
generale. In questo sottogruppo, gli antipsicotici sono ampiamente prescritti: nonostante siano
autorizzati esclusivamente per ...
Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply
(2018)
Standardised mean differences can be difficult to translate into clinical practice. As reported in the Cochrane handbook, the mean difference (or more correctly, difference in means) measures the absolute difference between ...
Building trust in artificial intelligence and new technologies in mental health
(2022-04)
In 2019, the Topol review was published on behalf of the secretary of state for health and social care in the UK, preparing the healthcare workforce to deliver the digital future.1 A multidisciplinary team of experts, ...
Generating comparative evidence on new drugs and devices before approval
(2020-03)
Fewer than half of new drugs have data on their comparative benefits and harms against existing treatment options at the time of regulatory approval in Europe and the USA. Even when active-comparator trials exist, they ...
Examining the Effectiveness of Web-Based Interventions to Enhance Resilience in Health Care Professionals: Systematic Review
(2022-07)
Background: Internationally, the impact of continued exposure to workplace environmental and psychological stressors on
health care professionals’mental health is associated with increased depression, substance misuse, ...
Explainable artificial intelligence for mental health through transparency and interpretability for understandability
(2023-01)
The literature on artificial intelligence (AI) or machine learning (ML) in mental health and psychiatry lacks consensus on what
“explainability” means. In the more general XAI (eXplainable AI) literature, there has been ...